Schering PEG-Intron Phase IV Trial To Study African Americans
Executive Summary
Schering-Plough will study whether the hepatitis C treatment PEG-Intron produces lower response rates in African American patients following approval of the pegylated interferon.
You may also be interested in...
PEG-Intron/Rebetol Subgroups Should Be Analyzed, Cmte. Says
FDA's Antiviral Drugs Advisory Committee would like to see an analysis of patient subgroups treated with Schering-Plough's PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin)
PEG-Intron/Rebetol Subgroups Should Be Analyzed, Cmte. Says
FDA's Antiviral Drugs Advisory Committee would like to see an analysis of patient subgroups treated with Schering-Plough's PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin)
Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen
Schering-Plough will study alternative dosing regimens for PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin) following approval of the hepatitis C combination therapy.